Quick Facts: Тевастор

• Supports management of elevated cholesterol levels in the blood.
• Assists in reducing the risk of major cardiovascular events.
• Intended for use alongside dietary adjustments.

---

Тевастор (whose active ingredient is rosuvastatin) is a medication intended to support the reduction of elevated levels of total cholesterol and low-density lipoprotein (LDL) cholesterol (often referred to as “bad” cholesterol) in the bloodstream. Maintaining cholesterol within a target range is considered a key element of comprehensive cardiovascular health management.

The medication is indicated for use in adult patients who have not achieved sufficient lipid management through diet alone. By assisting in the control of lipid levels, the drug may help mitigate the risk factors associated with serious health outcomes.

One of the main therapeutic uses involves reducing the potential for major cardiovascular events in individuals who are at an elevated risk. This includes contributing to the management of conditions such as heart attack and stroke risk in those with pre-existing risk factors, when utilized as part of a clinician-supervised treatment plan.

Who can and cannot use Тевастор?

Eligibility for Тевастор (Rosuvastatin) is strictly defined by regulatory documents based on patient health status and demographic factors.

Classification	Status and Eligibility Rules (Official Labeling)
Absolute Contraindications	Use is prohibited in patients with active liver disease, known hypersensitivity to the drug, women who are pregnant, and nursing mothers.
Condition-Specific Rules	The drug is restricted in patients with severe renal impairment (creatinine clearance < 30 mL/min), where the dose must not exceed 10 mg once daily. Caution is warranted in patients with uncontrolled hypothyroidism or other factors predisposing to myopathy.
Age-Related Eligibility	Use is allowed for adults and pediatric patients aged 8 years and older with Heterozygous Familial Hypercholesterolemia (HeFH). Use is allowed for pediatric patients aged 7 years and older with Homozygous Familial Hypercholesterolemia (HoFH). Safety and efficacy are not established for children younger than 7 years of age.
Special Populations	A lower starting dose of 5 mg should be considered for Asian patients due to documented increased systemic exposure. Caution is advised for patients aged 65 years and older due to increased risk of muscle effects.

The regulatory profile defines eligibility by establishing absolute non-eligibility through contraindications and mandating conditional use through dosage restrictions for populations such as those with severe kidney impairment. This structure ensures that use is strictly defined by official clinical and physiological criteria.

Interactions with other medicines and products

Тевастор (Atorvastatin) is metabolized primarily by the Cytochrome P450 3A4 (CYP3A4) enzyme system, which makes its plasma concentrations susceptible to changes from other drugs that affect this pathway. Concomitant use with strong inhibitors of CYP3A4 or certain transporters, such as Cyclosporine, Macrolide Antibiotics (Clarithromycin, Erythromycin), Azole Antifungals (Itraconazole), or certain HIV/HCV Protease Inhibitors, can significantly increase the risk of serious muscle toxicity, including myopathy and rhabdomyolysis.

Regulatory documents outline specific dose-based restrictions for these interactions to mitigate risk:

Interacting Product Category	Maximum Atorvastatin Dose
Cyclosporine, Tipranavir/Ritonavir, Glecaprevir/Pibrentasvir	Avoid or Do not exceed 10 mg/day
Clarithromycin, Itraconazole, Elbasvir/Grazoprevir, Saquinavir/Ritonavir, Darunavir/Ritonavir, Fosamprenavir/Ritonavir	Do not exceed 20 mg/day
Nelfinavir	Do not exceed 40 mg/day

Caution is also required when co-administering with Fibric Acid Derivatives or Colchicine due to an additive risk of muscle effects. Patients taking Digoxin or Oral Contraceptives (containing norethindrone and ethinyl estradiol) should be monitored, as Atorvastatin may increase the plasma levels of these medications. The drug Rifampin must be co-administered simultaneously with Atorvastatin to maintain drug efficacy. Excessive consumption of Grapefruit Juice should be avoided due to its potential to increase Atorvastatin exposure.

The pharmacological action of Тевастор (rosuvastatin) is focused primarily on the liver. The drug functions as a competitive inhibitor of HMG-CoA reductase, the enzyme that regulates the rate-limiting step in the mevalonate pathway of cholesterol biosynthesis. This molecular inhibition results in a reduction in the endogenous production of cholesterol within the hepatocytes.

The resulting decrease in intracellular cholesterol concentration triggers a cellular feedback mechanism, leading to the upregulation of Low-Density Lipoprotein (LDL) receptors on the hepatocyte surface. This increase in receptor expression enhances the liver's capacity to capture and remove circulating LDL-C particles from the bloodstream, resulting in a systemic reduction in the concentration of these lipoproteins. Furthermore, the drug modulates cellular activity within the blood vessel walls, influencing inflammatory mediators and affecting endothelial function.

This combined effect of reduced synthesis and increased clearance establishes a net alteration in the systemic lipid dynamics.

How Тевастор is Used: Administration Guidelines

Тевастор, which contains the active ingredient rosuvastatin, is administered following guidelines regarding its dose, frequency, and use conditions. The medication is available as film-coated tablets in strengths of 5 mg, 10 mg, 20 mg, and 40 mg.

---

Administration Protocol

Parameter	Instruction
Route and Form	Oral administration via film-coated tablets
Dosing Frequency	Taken once daily as a single dose
Timing and Food	May be taken with or without food and at any time of day
Standard Starting Dose	Typically 10 mg or 20 mg once daily
Maximum Dose	40 mg once daily, reserved for patients who have not achieved goals with the 20 mg dose

---

Use Principles and Adjustments

Dosage adjustments, or titration, should be conducted only after a minimum interval of two to four weeks has passed since the previous dose change. This ensures sufficient time for the lipid-lowering effects to stabilize before further modification. The maximum dose is subject to restrictions in specific patient populations: individuals with severe renal impairment (non-dialysis) should not exceed 10 mg once daily, and a starting dose of 5 mg should be considered for patients of Asian descent.

For a missed dose, the guidance is to resume the treatment schedule with the next regularly scheduled dose without taking an extra tablet. The tablet must be swallowed whole.

This structured approach defines the standardized oral regimen for rosuvastatin, outlining the established boundaries for administration and dose adjustment.

Research Evidence / Overview of Studies for Тевастор (Rosuvastatin)

---

Evidence for Managing Elevated Blood Lipids (Cholesterol)

Research has been conducted in studies where Тевастор was evaluated in relation to changes in cholesterol and other fat molecules in the blood. Studies have primarily taken the form of randomized controlled trials (RCTs), where patient groups were randomly assigned to receive rosuvastatin or a comparison treatment, such as placebo or another statin medicine. These trials researched whether taking Тевастор was associated with certain measurements, known as biomarkers, including low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides.

Findings from these short-term studies describe patterns observed in LDL-C and other key lipids. Systematic reviews summarize these findings, which contribute to the broader evidence landscape regarding changes in blood lipid profiles. However, many of these initial trials had follow-up durations that were limited, often lasting only a few weeks to a few months. This means that while these studies provide insight into short-term changes in blood markers, they provide limited information for long-term outcomes.

---

Evidence for Preventing Major Cardiovascular Events

Beyond monitoring changes in blood lipids, large-scale, long-duration research was evaluated in whether the use of Тевастор was associated with differences in the occurrence of serious heart-related events. These trials were studied for their potential to show patterns related to events such as nonfatal heart attack, nonfatal stroke, and cardiovascular death. Primary prevention studies explored adults who did not have established heart disease but who had other risk factors, including elevated levels of an inflammatory biomarker called high-sensitivity C-reactive protein (hs-CRP).

One foundational trial was observed in a research setting where the study was concluded earlier than its original design plan. While these findings contribute to the broader evidence landscape regarding event prevention, the early conclusion of the primary study meant that the long-term effects are not fully established based on that specific trial's duration. The findings describe group patterns, not individual predictions, and the results apply only to the populations studied.

---

Key Limitations and Areas of Research Uncertainty

The research base has specific limitations that scientists continue to study. For many of the hard outcomes, the follow-up durations were limited. Additionally, while the large studies enrolled broad populations, the data for certain groups remain insufficient, meaning subgroup findings are uncertain or are based on modest sample sizes. Some comparative evidence was associated with mixed findings when looking at overall safety and specific metabolic changes in at-risk participants, even while cardiovascular event rates remained comparable to other therapies studied. The evidence highlights what is known—and what is still uncertain—about the long-term and comparative patterns of this medicine.

Common questions about Тевастор (FAQ)

---

Q: Do I need to take Тевастор every day?

According to official regulatory documents, this medicine is designed to be taken once daily as a single dose. Treatment for managing blood lipid levels is generally considered a long-term regimen to maintain the desired effect.

---

Q: How long does it usually take to see a change in cholesterol test results after starting Тевастор?

Studies and official information indicate that the full therapeutic effect on blood lipid levels is typically seen within two to four weeks of starting treatment. Regulatory documents indicate that dose adjustments are typically made after this time frame to ensure the lipid-lowering effects have stabilized.

---

Q: Are there any special warnings about Тевастор and alcohol consumption?

Official labeling advises caution when using the drug if a patient consumes substantial quantities of alcohol. This warning is related to the potential for increased risk of liver-related problems, as the medicine affects the liver.

---

Q: How is Тевастор different from other statin drugs like atorvastatin?

Тевастор (rosuvastatin) is recognized as a high-potency statin. Pharmacological data describes it as being more water-soluble (hydrophilic), and its structure and properties suggest its action is largely confined to the liver.

---

Q: Does Тевастор affect blood sugar levels or diabetes risk?

Regulatory sources mention that statins, including this medicine, have been associated with increases in certain blood glucose markers (like HbA1c and fasting serum glucose). Official information notes reports of new-onset diabetes mellitus in some patients.

---

Q: Does Тевастор affect the kidneys over time?

Regulatory documents describe reports of proteinuria and hematuria (protein and blood in the urine, respectively), often transient, which are observations related to kidney function. Dose restrictions are in place for patients who already have severe renal (kidney) impairment.

---

Q: Is hair loss listed as a side effect of Тевастор?

Yes, regulatory sources list alopecia (hair loss) as an adverse reaction. Official sources list this effect under a rare or very rare frequency.

---

Q: Is it safe to take supplements like red yeast rice or niacin with Тевастор?

Official labeling advises caution when using the drug alongside high-dose niacin (nicotinic acid), as the combination can increase the risk of muscle side effects. Red yeast rice contains a substance chemically similar to statins; its combination is a known area of potential additive effect.

---

Q: Can Тевастор be cut in half if the dose is too strong?

The official administration guidance states that the tablet is formulated to be swallowed whole. Regulatory guidance is to avoid crushing, chewing, or splitting the tablet.

---

Q: Is Тевастор the same as Crestor (rosuvastatin)?

Тевастор contains the active ingredient rosuvastatin. Crestor is a widely recognized brand name for the same active ingredient. Both are formulations of the same active ingredient, rosuvastatin.

---

Q: Does Тевастор have a generic equivalent available?

Yes, the active ingredient in Тевастор, which is rosuvastatin, is available in multiple generic formulations, in addition to brand-name products.

---

Q: Are there any food restrictions besides grapefruit while using Тевастор?

The official labeling specifies a potential interaction with antacids containing aluminum and magnesium, which can lower the medicine’s concentration in the body. Official labeling notes that antacids containing aluminum and magnesium can reduce the medicine's plasma concentration. Some documents suggest taking antacids a few hours after the medicine. The medicine can otherwise be taken with or without food.

---

Q: Does Тевастор interact with birth control pills?

Official information states that co-administration with oral contraceptives can increase the concentration of certain hormones in the blood. Females who are of reproductive potential are advised in regulatory documents to use effective contraception during treatment.

---

Q: Does Тевастор work immediately after the first dose?

While the medicine begins its action soon after administration, a measurable lowering of LDL-C (low-density lipoprotein cholesterol) in blood tests is typically seen within one week, with the maximum effect usually occurring by two to four weeks.

---

Q: Is Тевастор related to improving blood flow?

In addition to its primary function of reducing cholesterol, studies and official information show the medicine can modulate cellular activity within the blood vessel walls. This influence on inflammatory mediators is related to its effect on endothelial function (the health of the inner lining of blood vessels).

---

Q: Is Тевастор used to treat high triglycerides?

Yes, the drug is officially indicated for reducing elevated levels of triglycerides in the bloodstream, in addition to addressing other abnormal fat levels (dyslipidemia).

---

Q: Is Тевастор approved for use in children or adolescents?

Regulatory documents indicate approval for specific pediatric patients, generally those aged 7 years and older with inherited forms of high cholesterol (Familial Hypercholesterolemia).

---

Q: Does Тевастор help with inherited high cholesterol conditions?

Yes, the drug is specifically indicated for the treatment of elevated cholesterol levels associated with Familial Hypercholesterolemia (HeFH and HoFH). These are genetic conditions that cause very high cholesterol.

---

Q: Is it normal to feel tired when first starting Тевастор?

Asthenia (weakness) is listed in regulatory documents as one of the commonly reported adverse reactions in clinical trials. Concerns about side effects are typically discussed with a healthcare provider.

---

Q: Does Тевастор have a role in treating conditions other than high cholesterol?

Yes, according to official indications, the drug is used to reduce the risk of major cardiovascular events, such as heart attack and stroke, in adults who have not previously been diagnosed with heart disease but have multiple risk factors.

---

Q: What tests are usually done before starting Тевастор?

Official labeling advises that liver enzyme tests (hepatic transaminases) should be conducted before starting therapy.

---

Q: What are the common signs of a liver problem that patients are advised to watch for?

Regulatory information advises patients to be aware of symptoms that could signal liver problems. These may include unusual fatigue or weakness, loss of appetite, upper belly pain, dark urine, and yellowing of the skin or eyes (jaundice).

---

Official Storage and Disposal Instructions

Tevastor (rosuvastatin calcium tablets) must be stored according to specific regulatory requirements to maintain its integrity and safety.

Element	Mandatory Condition
Temperature	Store at controlled room temperature (20 C to 25 C).
Protection	Keep protected from excess moisture and light; do not freeze.
Container	Keep the medicine in its original container and ensure the cap is tightly closed.

The regulatory profile mandates that all medication be stored out of the sight and reach of children to prevent accidental exposure.

For disposal of unused or expired tablets, official guidelines recommend using a drug take-back program as the preferred method. If a take-back option is unavailable, the tablets should be mixed with an undesirable substance (such as used coffee grounds) and placed into a sealed container before discarding in the household trash. The medication should not be flushed down the toilet or poured into a drain unless specific instructions state otherwise.